Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study

The American Journal of Gastroenterology 2026 Open access

Read full text
Authors: Franco Scaldaferri, Federica Di Vincenzo, M Aloi, M. Ascolani, Paola Balestrieri, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Emma Calabrese, R Cannatelli, Flavio Caprioli
+44 more M. Cappello, Michele Cicala, Ferdinando D’Amico, Silvio Danese, Alice De Bernardi, F.R. De Filippo, F Desideri, Dhanai Di Paolo, A. Di Sario, Massimo Claudio Fantini, Concetta Ferracane, Stefano Festa, Gionata Fiorino, Roberto Gabbiadini, Andrea Geccherle, Viviana Gerardi, Emiliano Giangreco, Antonietta Gerarda Gravina, L. Laterza, Loris Riccardo Lopetuso, Irene Marafini, Mauro Mastronardi, Marco Mendolaro, M. Merli, Giammarco Mocci, S. Onali, Maria Francesca Onidi, Luca Pastorelli, Alessandra Piagnani, Mariabeatrice Principi, Daniela Pugliese, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Fabrizio Santagata, Edoardo Vincenzo Savarino, Rocco Spagnuolo, A Tursi, A. Panarese, S. Mazzuoli, Angela Variola, Chiara Viganò, Alessandro Armuzzi, on behalf of the RESOLVE Study Group
DOI: 10.14309/ajg.0000000000003969
Cited by: 4
References: 48

Abstract

INTRODUCTION: To assess the effectiveness and safety of Risankizumab (RZB) in a large, nationwide real-world cohort of patients with Crohn's disease (CD). METHODS: We conducted a multicenter, retrospective observational cohort of adults initiating RZB with assessments at weeks 12, 26, and 52. Coprimary end points were (i) week-12 steroid-free clinical remission (SFCR) (Harvey-Bradshaw Index

Fields of Study & Subjects

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Biosimilars and Bioanalytical Methods

Publication details

Journal / source
The American Journal of Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Publication date
18 February 2026
Language
EN